Finance

Biotechnology company reports third quarter net loss of $5.7 million

Published in AIDS Weekly, December 5th, 2005

Targeted Genetics Corporation (TGEN) announced its financial results for the third quarter ended September 30, 2005. For the quarter, the company reported a net loss of $5.7 million, or $0.07 per share, compared to $2.7 million, or $0.03 per share for the third quarter of 2004.

For the 9 months ended September 30, 2005, the company reported a net loss of $15.6 million, or $0.18 per share, compared to $12.0 million, or $0.15 per share for the same period in 2004. As of September 30, 2005, cash and cash equivalents were $17.2 million, compared to $34.1 million at December 31, 2004.

Revenue for the 3 months ended September 30, 2005 was $1.5 million,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2005-12-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry